finance.yahoo.com
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to expand into IBD markets.
Availability direct to consumers could change access and lead to more patients ordering tests without immediate clinician visits.
Adults with IBS or gut symptoms, patients with or interested in IBD (Crohn’s, ulcerative colitis), clinicians who advise patients on diagnostic testing and diet, and researchers or industry watchers tracking diagnostics and med‑tech business developments.
What To Know
Biomerica announced fiscal results and promoted its inFoods® IBS at-home blood test, including recent patent allowances covering GERD, Crohn’s disease, and ulcerative colitis and claims about clinical studies at major centers.
The release describes the test as non‑invasive, physician‑guided, and intended to identify food triggers for IBS symptoms (pain, bloating, diarrhea, constipation). It also notes direct‑to‑consumer availability and ongoing distribution discussions.
The company frames these patents as addressing large market opportunities and highlights improved financial metrics and cost reductions for the quarter.
The announcement references clinical work at Mayo Clinic, Beth Israel Deaconess, Houston Methodist, and University of Michigan but does not include full study details or peer‑reviewed publication links in this press release.
If you’re considering an at‑home test like inFoods®, discuss results and any diet changes with your clinician before making treatment or dietary decisions. The press release is primarily a company financial update and marketing summary rather than a detailed clinical report.
This is a corporate press release focused on financial results and product promotion. The clinical study mentions major hospitals but the release does not provide full data, peer‑reviewed publications, or regulatory approvals for diagnostic claims. The inFoods® test is described as physician‑guided despite direct‑to‑consumer ordering.
No treatment recommendations or detailed study outcomes are presented here.
